Loading chat...
NY S07710
Bill
Status
6/19/2018
Primary Sponsor
Neil Breslin
Click for details
AI Summary
-
Requires physicians and authorized practitioners to test cancer patients for dihydropyrimidine dehydrogenase deficiency prior to administering fluoropyrimidine or other antimetabolites.
-
Mandates that all medical insurance policies in New York covering cancer chemotherapy include coverage for dihydropyrimidine dehydrogenase deficiency testing prior to fluoropyrimidine or antimetabolite treatment.
-
Applies the insurance coverage requirement to policies issued by medical expense indemnity corporations, hospital service corporations, and health service corporations.
-
Authorizes the Social Services Commissioner to establish standards and guidelines for providing dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program.
-
Takes effect on the 120th day after becoming law, with immediate authorization for any necessary rule or regulation amendments to implement the act.
Legislative Description
Requires dihydropyrimidine dehydrogenase deficiency testing prior to fluoropyrmidine or other antimetabolite treatment; requires policies and contracts of insurance to include coverage for dihydropyrimidine dehydrogenase deficiency testing; provides for dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program.
Last Action
referred to health
6/19/2018